Using our previously published model in which we are able to create a KMT2A::AFF1 leukemia de novo using CRISPR editing in human fetal hematopoietic stem and progenitor cells,38 we analyzed 2 leukemic samples derived from the same biological donor to determine whether they would still exhibit divergent enhancer landscapes. The gene discussed is AFF1; the disease is leukemia.